Skip to main content
Disciplines
Automotive Business IT + Informatics Construction + Real Estate Electrical Engineering + Electronics Energy + Sustainability Insurance + Risk Finance + Banking Management + Leadership Marketing + Sales Mechanical Engineering + Materials
Events
DE
EN
Books
Journals
Topic Page
Marketing
Start single access now
Access for companies
EXTENDED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 5/2017

28-11-2016

Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia

Authors: Zalmai Hakimi, Mike Herdman, Marco Pavesi, Nancy Devlin, Jameel Nazir, Chris Hoyle, Isaac A. O. Odeyemi

Published in: Quality of Life Research | Issue 5/2017

Log in

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

Objectives

To assess changes in the health status of men with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) using the EQ-5D-3L and OAB-5D instruments and to evaluate the sensitivity of the instruments.

Methods

Data were available from a large randomised phase III trial of men with moderate-to-severe storage and voiding LUTS/BPH (NEPTUNE). Men received a fixed-dose combination of solifenacin 6 mg plus oral controlled absorption system (OCAS™) formulation of tamsulosin (TOCAS, 0.4 mg), TOCAS monotherapy or placebo and completed the EQ-5D-3L and OAB-5D at baseline and weeks 4, 8 and 12. Analysis of covariance was used to estimate changes in EQ-5D-3L Index, EQ-VAS and OAB-5D. Changes in dimension level were summarised using the Paretian Classification of Health Change (PCHC).

Results

Improved health-related quality of life from baseline was seen in all treatment arms on EQ-5D-3L and OAB-5D at week 12, although only OAB-5D showed statistically significant differences between active treatment and placebo, both on the index score and using the PCHC approach. Effect sizes in the active treatment groups were large (>0.8) on OAB-5D but small (≈0.2) on EQ-5D-3L. EQ-5D-3L showed a very high ceiling effect (45% of men reported full health at baseline) and a substantial proportion of these men reported improvements at week 12 in several dimensions of OAB-5D.

Conclusions

A large ceiling effect on EQ-5D-3L substantially limited its sensitivity in this population. OAB-5D proved more sensitive to changes in health status and could be considered a complement to ED-5D-3L as a source of utilities for health economic modelling.
previous article Does the EQ-5D capture the effects of physical and mental health status on life satisfaction among older people? A path analysis approach
next article Employing quality control and feedback to the EQ-5D-5L valuation protocol to improve the quality of data collection

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

inform now
Literature
1.
Abrams, P., Manson, J., & Kirby, M. G. (2012). Incidence and epidemiology of storage lower urinary tract symptoms. European Urological Review, 7, 50–54.
2.
Peters, T. J., Donovan, J. L., Kay, H. E., Abrams, P., de la Rosette, J. J., Porru, D., et al. (1997). The International Continence Society “benign prostatic hyperplasia” study: The bothersomeness of urinary symptoms. Journal of Urology, 157, 885–889.CrossRefPubMed
3.
4.
5.
Garraway, W. M., Russell, E. B., Lee, R. J., Collins, G. N., McKelvie, G. B., Hehir, M., et al. (1993). Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. British Journal of General Practice, 43, 318–321.PubMedPubMedCentral
6.
McVary, K. T. (2006). BPH: Epidemiology and comorbidities. American Journal of Managed Care, 12, S122–S128.PubMed
7.
Schipper, H., Clinch, J. J., & Olweny, C. L. M. (1996). Quality of life studies: Definitions and conceptual issues. In B. Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven Publishers.
8.
Welch, G., Weinger, K., & Barry, M. J. (2002). Quality-of-life impact of lower urinary tract symptom severity: Results from the health professionals follow-up study. Urology, 59, 245–250.CrossRefPubMed
9.
Coyne, K. S., Wein, A. J., Tubaro, A., Sexton, C. C., Thompson, C. L., Kopp, Z. S., et al. (2009). The burden of lower urinary tract symptoms: Evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU International, 103, 4–11.CrossRefPubMed
10.
Wein, A. J., Coyne, K. S., Tubaro, A., Sexton, C. C., Kopp, Z. S., & Aiyer, L. P. (2009). The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU International, 103, 33–41.CrossRefPubMed
11.
Trueman, P., Hood, S. C., Nayak, U. S., & Mrazek, M. F. (1999). Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’, and their effect on quality of life in a community-based survey of men in the UK. BJU International, 83, 410–415.CrossRefPubMed
12.
Girman, C. J., Jacobsen, S. J., Tsukamoto, T., Richard, F., Garraway, W. M., Sagnier, P. P., et al. (1998). Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology, 51, 428–436.CrossRefPubMed
13.
Boyle, P., Robertson, C., Mazzetta, C., Keech, M., Hobbs, R., Fourcade, R., et al. (2003). The relationship between lower urinary tract symptoms and health status: The UREPIK study. BJU International, 92, 575–580.CrossRefPubMed
14.
Lukacs, B., Cornu, J. N., Aout, M., Tessier, N., Hodée, C., Haab, F., et al. (2013). Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: A comprehensive population study. European Urology, 64, 493–501.CrossRefPubMed
15.
Drummond, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005). Methods for the economic evaluation of health care programmes (3rd ed.). Oxford: Oxford University Press.
16.
17.
Castro-Díaz, D., Callejo, D., Cortés, X., & Pérez, M. (2014). Study of quality of life in patients with benign prostatic hyperplasia under treatment with silodosin. Actas Urológicas Españolas, 38, 361–366.PubMed
18.
Fourcade, R. O., Lacoin, F., Rouprêt, M., Slama, A., Le Fur, C., Michel, E., et al. (2012). Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World Journal of Urology, 30, 419–426.CrossRefPubMed
19.
Coyne, K., Revicki, D., Hunt, T., Corey, R., Stewart, W., Bentkover, J., et al. (2002). Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Quality of Life Research, 11, 563–574.CrossRefPubMed
20.
Young, T., Yang, Y., Brazier, J. E., Tsuchiya, A., & Coyne, K. (2009). The first stage of developing preference-based measures: Constructing a health-state classification using Rasch analysis. Quality of Life Research, 18, 253–265.CrossRefPubMed
21.
Desroziers, K., Aballéa, S., Maman, K., Nazir, J., Odeyemi, I., & Hakimi, Z. (2013). Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder. Health and Quality of Life Outcomes, 11, 200.CrossRefPubMedPubMedCentral
22.
van Kerrebroeck, P., Chapple, C., Drogendijk, T., Klaver, M., Sokol, R., Speakman, M., et al. (2013). Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: Efficacy and safety results from the randomised controlled NEPTUNE trial. European Urology, 64, 1003–1012.CrossRefPubMed
23.
24.
Chapple, C. R., Drake, M. J., van Kerrebroeck, P., Cardozo, L., Drogendijk, T., Klaver, M., et al. (2014). Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. BJU International, 113, 696–703.CrossRefPubMed
25.
Drake, M. J., Sokol, R., Coyne, K., Hakimi, Z., Nazir, J., Dorey, J., et al. (2016). Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: Results from the NEPTUNE study. BJU International, 117, 165–172.CrossRefPubMed
26.
Matza, L. S., Thompson, C. L., Krasnow, J., Brewster-Jordan, J., Zyczynski, T., & Coyne, K. S. (2005). Test-retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourology and Urodynamics, 24, 215–225.CrossRefPubMed
27.
Coyne, K. S., Matza, L. S., & Thompson, C. L. (2005). The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Quality of Life Research, 14, 849–855.CrossRefPubMed
28.
Yang, Y., Brazier, J., Tsuchiya, A., & Coyne, K. (2009). Estimating a preference-based single index from the Overactive Bladder Questionnaire. Value in Health, 12, 159–166.CrossRefPubMed
29.
Gudex, C. (2005). The descriptive system of the EuroQol instrument. In P. Kind, R. Brooks, & R. Rabin (Eds.), EQ-5D concepts and methods: A developmental history. Berlin: Springer.
30.
31.
Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research, 14, 1523–1532.CrossRefPubMed
32.
Hays, R. D., & Revicki, D. (2005). Reliability and validity (including responsiveness). In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials: Methods and practice (2nd ed.). New York: Oxford University Press.
33.
Cohen, J. (1998). Statistical power analysis for the behavioural sciences (2nd ed.). Hillsdale, NJ: L. Erlbaum Associates.
34.
Devlin, N. J., Parkin, D., & Browne, J. (2010). Patient-reported outcome measures in the NHS: New methods for analysing and reporting EQ-5D data. Health Economics, 19, 886–905.CrossRefPubMed
35.
Parkin, D., Devlin, N., & Rice, N. (2010). Statistical analysis of EQ-5D profiles: Does the use of value sets bias inference? Medical Decision Making, 30, 556–565.CrossRefPubMed
36.
Pavesi, M., Devlin, N., Hakimi, Z., Nazir, J., Herdman, M., Hoyle, C., et al. (2013). Understanding the effects on HR-QoL of treatment for overactive bladder: A detailed analysis of EQ-5D clinical trial data for mirabegron. Journal of Medical Economics, 16, 866–876.CrossRefPubMed
37.
Buckley, B.S., Lapitan, M.C., Glazener, C.M.; MAPS Trial Group. (2012). The effect of urinary incontinence on health utility and health-related quality of life in men following prostate surgery. Neurourology and Urodynamics, 31, 465–469.CrossRef
38.
Patrick, D. L., & Deyo, R. A. (1989). Generic and disease-specific measures in assessing health status and quality of life. Medical Care, 27, S217–S232.CrossRefPubMed
39.
Wiebe, S., Guyatt, G., Weaver, B., Matijevic, S., & Sidwell, C. (2003). Comparative responsiveness of generic and specific quality-of-life instruments. Journal of Clinical Epidemiology, 56, 52–60.CrossRefPubMed
40.
Metadata
Title
Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia
Authors
Zalmai Hakimi
Mike Herdman
Marco Pavesi
Nancy Devlin
Jameel Nazir
Chris Hoyle
Isaac A. O. Odeyemi
Publication date
28-11-2016
Publisher
Springer International Publishing
Published in
Quality of Life Research / Issue 5/2017
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1460-x

Other articles of this Issue 5/2017

Quality of Life Research 5/2017 Go to the issue

OriginalPaper

The impact of living arrangements on quality of life among Korean elderly: findings from the Korean Longitudinal Study of Aging (2006–2012)

OriginalPaper

Can in-the-moment diary methods measure health-related quality of life in Duchenne muscular dystrophy?

OriginalPaper

Evaluating and establishing national norms for mental wellbeing using the short Warwick–Edinburgh Mental Well-being Scale (SWEMWBS): findings from the Health Survey for England

OriginalPaper

The validation of a computer-adaptive test (CAT) for assessing health-related quality of life in children and adolescents in a clinical sample: study design, methods and first results of the Kids-CAT study

OriginalPaper

Factors associated with the quality of life of mothers of preterm infants with very low birth weight: a 3-year follow-up study

OriginalPaper

Does the EQ-5D capture the effects of physical and mental health status on life satisfaction among older people? A path analysis approach